The most common childhood
cancer is acute lymphoblastic leukemia (ALL). Chemotherapy-associated
hematological toxicity is well-known; however, there are few studies on
hematologic toxicity incidence in children with ALL. We investigated the
severity and incidence of hematologic toxicity during intense chemotherapy
processes in children treated with ALL IC-BFM 2009 protocol. The study included
41 leukemic children in standard (SR) and intermediate risk (IR) groups treated
between 2011 and 2015. During the induction period, the incidence of grade 4
toxicity in neutrophil count was 60%; the incidence of grade ≥ 3 toxicity in hemoglobin level was 34%; and the incidence of
grade ≥ 3 toxicity in the platelet count was 51%. Deep neutropenia duration was
36.6 ± 12.7 (18-68) days during the induction. 53% of the febrile neutropenic
(FEN) episodes developed during the induction period. There were no statistical
differences between SR and IR risk groups with respect to hemogram values deep
neutropenia duration and the number of FEN episodes (p > 0.05, all). There was a positive
correlation between the number of FEN episodes and duration of neutropenia.
During the induction, the mean neutrophil count remained between 0.5-1 × 109/L. FEN episodes
most commonly developed during the induction phase.
Cite this paper
Ozdemir, Z. C. , Kar, Y. D. , Turhan, A. B. and Bor, O. (2017). Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALL IC-BFM 2009 Protocol. Open Access Library Journal, 4, e3807. doi: http://dx.doi.org/10.4236/oalib.1103807.
Gaynon, P.S., Angiolillo, A.L., Carroll, W.L., et al. (2010) Long-Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983-2002: A Children’s Oncology Group Report. Leukemia, 24, 285-297. https://doi.org/10.1038/leu.2009.262
Castagnola, E., Fontana, V., Caviglia, I., et al. (2007) A Prospective Study on the Epidemiology of Febrile Episodes during Chemotherapy-Induced Neutropenia in Children with Cancer or after Hemopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 45, 1296-1304. https://doi.org/10.1086/522533
Yilmaz, S., Oren, H., Demirciogu, F., et al. (2008) Assessment of Febrile Neutropenia Episodes in Children with Acute Leukemia Treated with BFM Protocols. Pediatric Hematology and Oncology, 25, 195-204.
Ranan, Z.A., Rabbani, M.W., Sheikh, M.A., et al. (2009) Outcome of Childhood Acute Lymphoblastic Leukemia after Induction Therapy 3 Years Experience at e Single Paediatric Oncology Centre. Journal of Ayub Medical College Abbottabad, 21, 150-153.
Ozdemir, N., Tüysüz, G., Celik, N., et al. (2016) Febrile Neutropenia in Children with Acute Lymphoblastic Leukemia: Single Center Experience. Turkish Pediatric Arsivi, 51, 79-86.
Li, S.D., Chen, Y.B., Li, Z.G., et al. (2015) Infections during Induction Therapy of Protocol CCLG 2008 in Childhood Acute Lymphoblastic Leukemia: A Single Center Experience with 256 Cases in China. Chinese Medical Journal, 128, 472-476. https://doi.org/10.4103/0366-6999.151085
Bodey, G.P., Buckley, M., Sathe, Y.S., et al. (1966) Quantitative Relationships between Circulating Leukocytes and Infection in Patients with Acute Leukemia. Annals of Internal Medicine, 64, 328-340. https://doi.org/10.7326/0003-4819-64-2-328
Lyman, G.H., Kuderer, N.M. and Balducci, L. (2002) Cost-Benefit Analysis of Granulocyte Colony-Stimulating Factor in the Management of Elderly Cancer Patients. Current Opinion in Hematology, 9, 207-214. https://doi.org/10.1097/00062752-200205000-00006
Weycker, D., Barron, R., Kartashov, A., et al. (2014) Incidence, Treatment and Consequences of Chemotherapy-Induced Febrile Neutropenia in the Inpatient and Outpatient Settings. Journal of Oncology Pharmacy Practice, 20, 190-198. https://doi.org/10.1177/1078155213492450
Buffler, P.A., Kwan, M.L., Reynods, P., et al. (2005) Environmental and Genetic Risk Factors for Childhood Leukemia: Appraising the Evidence. Cancer Investigation, 23, 60-75. https://doi.org/10.1081/CNV-46402
Ribera, J.M., Oriol, A., Sanz, M.A., et al. (2008) Comparison of the Results of the Treatment of Adolescents and Young Adults with Standard Risk Acute Lymphoblastic Leukemia with the Programa Espanol de Tratamiento en Hematologia Pediatric Based Protocol ALL-96. Journal of Clinical Oncology, 28, 1843-1849. https://doi.org/10.1200/JCO.2007.13.7265
Tang, J.Y., Gu, L.J., Xue, H.L., et al. (2009) Report on Induction Efficacy of Protocol ALL-2005 and Middle Term Follow-Up of 158 Cases of Childhood Acute Lymphoblastic Leukemia. Chinese Journal of Hematology, 30, 289-293.
Nakamura, S., Gelber, R.D. and Blattner, S. (2000) Long-Term Follow-Up and Infectious Complications of Therapy for Acute Lymphoblastic Leukemia in Children. International Journal of Pediatric Hematology/Oncology, 6, 321-330.
Burnett, A.K., Russel, N.H., Hills, R.K., et al. (2015) A Randomized Comparison Daunorubicin 90 mg/m2 vs. 60 mg/m in AML Induction: Results from the UKNCRIAML 17 Trial in 1206 Patients. Blood, 125, 3878-3885. https://doi.org/10.1182/blood-2015-01-623447
Miller, C.B., Jones, R.J., Piantadosi, S., et al. (1990) Decreased Erythropoietin Response in Patients with the Anemia of Cancer. The New England Journal of Medicine, 322, 1689-1692. https://doi.org/10.1056/NEJM199006143222401
Wu, Y., Aravind, S., Ranganathan, G., et al. (2009) Anemia and Thrombocytopenia in Patients Undergoing Chemotherapy for Solid Tumors: A Descriptive Study of a Large Outpatient Oncology Practice Database, 2000-2007. Clinical Therapeutics, 31, 2416-2432.